ストックスクリーナーアプリを入手
2.34
3.70%
-0.09
前日終値:
$2.43
開ける：
$2.5
24時間の取引高:
2.66M
Relative Volume:
2.79
時価総額：
$78.55M
収益：
-
当期純損益:
$-51.50M
株価収益率:
-0.585
EPS:
-4
ネットキャッシュフロー:
$-47.10M
1週間 パフォーマンス:
+23.16%
1か月 パフォーマンス:
+3.08%
6か月 パフォーマンス:
+25.13%
1年 パフォーマンス:
-69.53%
1日の値動き範囲:
$2.22
$2.50
1週間の範囲:
$1.92
$2.50
52週間の値動き範囲:
$0.87
$8.32
Outlook Therapeutics Inc Stock (OTLK) Company Profile
名前
Outlook Therapeutics Inc
セクター
電話
(609) 619-3990
住所
111 S. WOOD AVENUE, ISELIN, NJ
OTLK を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
2.34 | 104.13M | 0 | -51.50M | -47.10M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-02 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2024-03-27 | アップグレード | BTIG Research | Neutral → Buy |
| 2024-02-15 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2024-01-25 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-12-27 | アップグレード | CapitalOne | Equal Weight → Overweight |
| 2023-08-31 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2023-08-31 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-08-30 | ダウングレード | BTIG Research | Buy → Neutral |
| 2023-08-30 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-08-30 | ダウングレード | CapitalOne | Overweight → Equal Weight |
| 2023-08-30 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-07-13 | 開始されました | CapitalOne | Overweight |
| 2023-04-03 | 開始されました | Guggenheim | Buy |
| 2023-02-06 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-10-31 | 開始されました | BTIG Research | Buy |
| 2022-09-13 | 開始されました | Chardan Capital Markets | Buy |
| 2019-09-11 | 開始されました | Ladenburg Thalmann | Buy |
| 2019-05-16 | 開始されました | Oppenheimer | Outperform |
| 2019-04-22 | 開始されました | Ascendiant Capital Markets | Buy |
すべてを表示
Outlook Therapeutics Inc (OTLK) 最新ニュース
Outlook Therapeutics: Pivoting from R&D to Commercialization with LYTENAVA™ in Europe and FDA Approval on Horizon - AInvest
Outlook Therapeutics (OTLK) Maintains Rating by Chardan Capital - GuruFocus
Outlook Therapeutics shares rise 4.12% premarket after reporting financial results for the third quarter. - AInvest
Outlook Therapeutics Reports Q3 2025 Earnings and Milestones - TipRanks
Outlook Therapeutics Reports Q3 Revenue - AOL.com
Outlook Therapeutics Posts Q3 Revenue of $1.5mln, Meeting Estimates, and First-Ever Commercial Sales in Europe. - AInvest
Outlook Therapeutics Inc Reports Q3 2025 Earnings: EPS of -$0.55 - GuruFocus
Outlook Therapeutics Q3 FY2025 Financial Results and Corporate Update - TradingView
Outlook Therapeutics at a Strategic Inflection Point: Regulatory and Commercial Catalysts for Value Creation in the $4B+ Anti-VEGF Market - AInvest
Outlook Therapeutics reports Q3 net loss of $20.2mln, $1.5mln revenue. - AInvest
Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update - GlobeNewswire
Outlook's Eye Drug LYTENAVA Launches in Europe as Critical FDA Decision Approaches - Stock Titan
Reversal Traders Monitor Outlook Therapeutics Inc. for EntryChart Breakout Buy Signal Detection Confirmed - sundaytimes.kr
Outlook Therapeutics, Inc. shares rise 1.94% after-hours due to positive market sentiment. - AInvest
SHAREHOLDER ALERT: Levi & Korsinsky Reminds Outlook Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 2, 2024OTLK - ACCESS Newswire
Outlook Therapeutics Inc expected to post a loss of 39 cents a shareEarnings Preview - TradingView
Published on: 2025-08-04 15:25:16 - metal.it
What are analysts’ price targets for Outlook Therapeutics Inc. in the next 12 monthsUnlock high-yield investment opportunities - Jammu Links News
What institutional investors are buying Outlook Therapeutics Inc. stockTriple-digit profit margins - Jammu Links News
What are the latest earnings results for Outlook Therapeutics Inc.Game-changing capital returns - Jammu Links News
What is the dividend policy of Outlook Therapeutics Inc. stockFree Capital Allocation Plans - Jammu Links News
How volatile is Outlook Therapeutics Inc. stock compared to the marketExceptional portfolio growth - Jammu Links News
When is Outlook Therapeutics Inc. stock expected to show significant growthExplosive portfolio gains - Jammu Links News
Is Outlook Therapeutics Inc. a good long term investmentUnrivaled growth potential - Jammu Links News
How strong is Outlook Therapeutics Inc. company’s balance sheetCapitalize on fast-growing stocks today - Jammu Links News
What is the risk reward ratio of investing in Outlook Therapeutics Inc. stockFree Stock Chart Pattern Guide - Jammu Links News
What makes Outlook Therapeutics Inc. stock price move sharplyInvest confidently with expert support - Jammu Links News
What catalysts could drive Outlook Therapeutics Inc. stock higher in 2025Achieve breakthrough performance in the market - Jammu Links News
Should I hold or sell Outlook Therapeutics Inc. stock in 2025Capitalize on emerging market sectors - Jammu Links News
How does Outlook Therapeutics Inc. generate profit in a changing economyAchieve triple-digit returns with smart investing - Jammu Links News
What is Outlook Therapeutics Inc. company’s growth strategyPre Market Recommendation With Low Risk - Jammu Links News
Outlook Therapeutics, Inc. shares rise 1.95% premarket after Eli Lilly's Mounjaro shows heart benefits in a head-to-head study. - AInvest
What institutions are buying Outlook Therapeutics Inc. stock nowEntry Points For Growing Stocks Identified by Models - metal.it
Ichimoku Cloud Indicates Uncertainty Around Outlook Therapeutics Inc.Real Trader Watchlist of Hot Stocks Released - metal.it
What caused OTLK's net profit surge in Q3 2024? - AInvest
SHAREHOLDER ALERT: Potential Recovery for Outlook Therapeutics, Inc. (OTLK) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
How many analysts rate Outlook Therapeutics Inc. as a “Buy”Build your wealth with consistent stock growth - Jammu Links News
Outlook Therapeutics Inc. stock outlook for YEAR Pattern Recognition Based Market Move Prediction - Newser
Why is Outlook Therapeutics Inc. stock attracting strong analyst attentionInvest confidently with professional market insights - Jammu Links News
Published on: 2025-07-28 00:00:40 - Jammu Links News
Top Risks to Consider Before Buying Outlook Therapeutics Inc. StockSafe High Return Entry Points - Newser
Outlook Therapeutics Inc (OTLK) 財務データ
収益
当期純利益
現金流量
EPS
0.41%
0.88%
大文字化:
|
ボリューム (24 時間):